Devo33 Sunday, 07/15/18 02:52:15 PM Re: DDobserver post# 6061 Post # of 6120 This stock is currently 1/100+ from where it was a year and a half ago when success was being achieved. We all know the NSS represents the best acute SCI treatment available today. The Inspire study didn't fail the benefit standard in that there were numerous patients that benefited significantly. The safety standard however was not achieved. Clearly the NSS was not the obvious cause of the deaths or the FDA would not have authorized the 2.0. But any safety issues need to be figured out and that takes time to minimize risk going forward, Its not surprising we are still waiting for the first implant of 2.0. The money is available. The hospitals are still ready. Patients are available. The benefit has been clearly documented.....but so has the risk. If the numbers are correct, I am glad to see that the Institutional owner % is still quite high. 100X ROI by next summer! I know thats way too long for most of the posters on this board, You and I have been around for a long time and I still believe in the science, the inventors, and the benefit. Management is an unknown. I will stick around and see what happens, Should be plenty of trading volatility over the next year.